Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancer

被引：0
作者：
Li, Dangran [1 ,2 ]
Weng, Shiting [1 ,3 ]
Zeng, Kai [1 ]
Xu, Hanmiao [1 ]
Wang, Wenyueyang [1 ]
Shi, Jinsong [1 ]
Chen, Jinghua [1 ]
Chen, Chen [1 ]
机构：
[1] Jiangnan Univ, Sch Life Sci & Hlth Engn, Key Lab Carbohydrate Chem & Biotechnol, Minist Educ, Wuxi 214122, Peoples R China
[2] Nanjing Univ, Coll Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210029, Peoples R China
[3] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China
来源：
GENE | 2024年 / 895卷
关键词：
LncRNA; MicroRNA; Pancreatic ductal adenocarcinoma; Chemoresistance; Targeted therapy; Tyrosine kinase; ENDOTHELIAL GROWTH-FACTOR; GEMCITABINE RESISTANCE; C-MET; FACTOR RECEPTOR; EXPRESSION; PROMOTES; OVEREXPRESSION; SURVIVAL; CHEMORESISTANCE; PROGRESSION;
D O I：
10.1016/j.gene.2023.148007
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Pancreatic cancer (PC) is one of the most malignant tumors with a dismal survival rate, this is primarily due to inevitable chemoresistance. Dysfunctional tyrosine kinases (TKs) and long non-coding RNAs (lncRNAs) affect the drug resistance and prognosis of PC. Here, we summarize the mechanisms by which TKs or lncRNAs mediate drug resistance and other malignant phenotypes. We also discuss that lncRNAs play oncogenic or tumor suppressor roles and different mechanisms including lncRNA-proteins/microRNAs to mediate drug resistance. Furthermore, we highlight that lncRNAs serve as upstream regulators of TKs mediating drug resistance. Finally, we display the clinical significance of TKs (AXL, EGFR, IGF1R, and MET), clinical trials, and lncRNAs (LINC00460, PVT1, HIF1A-AS1). In the future, TKs and lncRNAs may become diagnostic and prognostic biomarkers or drug targets to overcome the drug resistance of PC.
引用
收藏
页数：11
相关论文
共 108 条
  • [91] LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway
    Xu, Fengyu
    Huang, Mengqi
    Chen, Qingyong
    Niu, Yi
    Hu, Yuhang
    Hu, Ping
    Chen, Ding
    He, Chi
    Huang, Kang
    Zeng, Zhu
    Tang, Jiang
    Wang, Fan
    Zhao, Yong
    Wang, Chunyou
    Zhao, Gang
    [J]. CANCER RESEARCH, 2021, 81 (22) : 5678 - 5691
  • [92] Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway
    Xu, Huiting
    Chen, Runzhi
    Shen, Qian
    Yang, Dongmei
    Peng, Hui
    Tong, Jin
    Fu, Qiang
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [93] LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma
    Yang, Fan
    Li, Xiaofang
    Zhang, Lingjuan
    Cheng, Lina
    Li, Xiuling
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2018, 137 (02) : 116 - 121
  • [94] Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review
    Yang, Jinshou
    Xu, Ruiyuan
    Wang, Chengcheng
    Qiu, Jiangdong
    Ren, Bo
    You, Lei
    [J]. CANCER COMMUNICATIONS, 2021, 41 (12) : 1257 - 1274
  • [95] lncRNA SLC7A11-AS1 Promotes Chemoresistance by Blocking SCFβ-TROP -Mediated Degradation of NRF2 in Pancreatic Cancer
    Yang, Qingzhu
    Li, Kai
    Huang, Xuemei
    Zhao, Chen
    Mei, Yu
    Li, Xinyuan
    Jiao, Lin
    Yang, Huanjie
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 19 : 974 - 985
  • [96] Epigenetic modulations of noncoding RNA: a novel dimension of Cancer biology
    Yang, Xiao
    Liu, Ming
    Li, Mengmeng
    Zhang, Sen
    Hiju, Hong
    Sun, Jing
    Mao, Zhihai
    Zheng, Minhua
    Feng, Bo
    [J]. MOLECULAR CANCER, 2020, 19 (01)
  • [97] Preclinical Efficacy of Anti-RON Antibody Drug-Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase
    Yao, Hang-Ping
    Feng, Liang
    Weng, Tian-Hao
    Hu, Chen-Yu
    Suthe, Sreedhar Reddy
    Mostofa, A. G. M.
    Chen, Ling-Hui
    Wu, Zhi-Gang
    Wang, Wei-Lin
    Wang, Ming-Hai
    [J]. MOLECULAR PHARMACEUTICS, 2018, 15 (08) : 3260 - 3271
  • [98] Increased m6A modification of lncRNA DBH-AS1 suppresses pancreatic cancer growth and gemcitabine resistance via the miR-3163/USP44 axis
    Ye, Xin
    Wang, Li-Ping
    Han, Cong
    Hu, Hao
    Ni, Chen-Ming
    Qiao, Guang-Lei
    Ouyang, Liu
    Ni, Jun-Sheng
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (06)
  • [99] Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207
    You, Lei
    Wang, Huanyu
    Yang, Gang
    Zhao, Fangyu
    Zhang, Jingcheng
    Liu, Ziwen
    Zhang, Taiping
    Liang, Zhiyong
    Liu, Changzheng
    Zhao, Yupei
    [J]. MOLECULAR ONCOLOGY, 2018, 12 (12): : 2147 - 2164
  • [100] Overexpression of c-met in the early stage of pancreatic carcinogenesis;: altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer
    Yu, Jun
    Ohuchida, Kenoki
    Mizumoto, Kazuhiro
    Ishikawa, Nami
    Ogura, Yasuhiro
    Yamada, Daisuke
    Egami, Takuya
    Fujita, Hayato
    Ohashi, Seiji
    Nagai, Eishi
    Tanaka, Masao
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (24) : 3878 - 3882
234567891011